

03 AUG 2005

HF4

IN THE UNITED STATES RECEIVING OFFICE (RO/US)
Designated/Elected Office (DO/EO/US)

U.S. National Stage of
International Application No.: PCT/US03/27975
International Filing Date: September 4, 2003
Earliest Priority Date: September 4, 2002
Applicants: Gordon D. Ross (deceased)
Title: CANCER THERAPY USING BETA GLUCAN AND
ANTIBODIES
Attorney's Docket No.: 3593.1001-008

Date: August 3, 2005

EXPRESS MAIL LABEL NO. EV 215897179 US

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

- ☐ under 37 CFR 1.129(a), or
(First/Second submission after Final Rejection)
- ☒ under 37 CFR 1.97(b), or
(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).
- ☐ under 37 CFR 1.97(c) together with either:
☐ a Statement under 37 CFR 1.97(e), as checked below, or
☐ a \$180.00 fee under 37 CFR 1.17(p), or
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- ☐ under 37 CFR 1.97(d) together with:
☐ a Statement under 37 CFR 1.97(e), as checked below, and
☐ a \$180.00 fee under 37 CFR 1.17(p), or
(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)
- ☐ under 37 CFR 1.97(i):
Applicant requests that the IDS and cited reference(s) be placed in the application
filewrapper.
(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
- ☒ Copies of the cited references, B1, C1 and C2, are enclosed.
- ☐ Copies of issued U.S. patents and published U.S. applications are not required and are not being provided.
- ☐ Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
- ☒ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
- ☐ The "concise explanation" requirement (non-English references) for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
- ☐ the explanation provided in the Specification.
- ☐ submission of the enclosed International Search Report.
- ☐ submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
- ☐ the enclosed English language abstract.

☐ Applicant requests that the following non-published pending applications be considered:

Examiner's
Initials

____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

Examiner

Date

- ☐ A copy of each above-cited application, including the current claims, is enclosed, except any application filed on or after June 30, 2003, which has been scanned into the PTO's Image File Wrapper (IFW) system and is available to the examiner.
- ☐ A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

- ☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- ☐ Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.
- ☒ Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Pamela A. Torpey
Pamela A. Torpey
Registration No.: 45,736
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated: August 3, 2005

PTO-1449 REPRODUCED

**INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION****August 3, 2005**

(Use several sheets if necessary)

ATTORNEY DOCKET NO.
3593.1001-008APPLICATION NO.
10/526,185FIRST NAMED INVENTOR
Gordon D. Ross (deceased)INTERNATIONAL FILING DATE
September 4, 2003EXAMINER
UnknownCONFIRMATION NO.
6460GROUP
Unknown**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION	
					YES	NO
	B1	WO 02/058711 A1	08-01-2002	Cheung		
	B2					
	B3					
	B4					
	B5					
	B6					
	B7					
	B8					
	B9					
	B10					
	B11					
	B12					
	B13					
	B14					
	B15					
	B16					
	B17					
	B18					
	B19					
	B20					
	B21					
	B22					
	B23					
	B24					

EXAMINER

DATE CONSIDERED

PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION August 3, 2005 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3593.1001-008		APPLICATION NO. 10/526,185	
	FIRST NAMED INVENTOR Gordon D. Ross (deceased)		INTERNATIONAL FILING DATE September 4, 2003	
	EXAMINER Unknown		CONFIRMATION NO. 6460	GROUP Unknown

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C1	Yadomae, T, "Structure and Biological Activities of Fungal Beta-1,3-glucans," <i>J. Pharm. Soc. of Japan</i> , 120(5): 413-431 (2000).
C2	Wang, S.C., <i>et al.</i> , "Targeting HER2: Recent Developments and Future Directions for Breast Cancer Patients," <i>Semin. Oncol.</i> , 28(6): 21-29 (2001).
C3	
C4	
C5	
C6	
C7	
C8	
C9	
C10	
C11	
C12	
C13	
C14	
C15	
C16	
C17	

EXAMINER	DATE CONSIDERED
----------	-----------------